Stockreport

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observe [Read more]